DynamicEd™ Expert Review of Emerging Biologic Therapies for COPD Management
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 15 Minutes
Overview
In this micro-activity, learners will engage with a 15-minute expert faculty podcast focused on the latest advancements in COPD management and novel therapeutics. Accompanying the podcast is an educational handout that highlights key elements from recent clinical trials to reinforce critical learning points. Integrated pre- and post-tests will assess learner proficiency and provide deeper insights into their confidence in treating COPD.
Target Audience
This educational initiative has been designed for pulmonology physicians, nurse practitioners, and physician assistants involved in the management of patients with COPD.
Learning Objectives
1. Review the safety, efficacy, and potential role of biologics for the treatment of COPD
Commercial Supporter
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi
Faculty
Stephanie Christenson, MD
Associate Professor of Medicine
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine
University of California San Francisco
San Francisco, CA
Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any continuing medical education (CME) to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Disclaimer
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
Stephanie Christenson, MD discloses being on a Speaker’s bureau with GSK but that relationship has ended, and being on a Speaker's bureau Sanofi, Regeneron. Advisory Boards with Sanofi, Regeneron, Astra Zeneca, and Glenmark but that relationship has ended and a Consultant with AZ during the past 24 months.
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Available Credit
- 0.25 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.